Announcement PDF ASX Announcement 22 April 2024 Investor webinar invite: Monash Sleep Health Symposium Highlights: ● ● ● ● Monash University and the Sleep Health Foundation will hold a Sleep Health Symposium in collaboration with Avecho to explore new treatment options for insomnia. The Symposium will unite world-leading experts to discuss sleep health in a national and global context, within key focus areas of insomnia, mental health, and unmet clinical needs. This event will support industry engagement as Avecho executes a pivotal Phase III Clinical Trial testing its oral proprietary CBD TPM®-enhanced softgel capsule for insomnia. Investors, shareholders and interested parties are invited to join the symposium virtually by registering HERE. Melbourne, Australia, 22 April 2024: Avecho Biotechnology Limited (ASX: AVE) (“Avecho” or the “Company”), focused on developing and commercialising innovative products using its proprietary Tocopheryl Phosphate Mixture (“TPM®”) drug delivery system, is pleased to invite its shareholders, investors and interested parties to a Sleep Health Symposium titled ‘Unmet Needs of Insomnia’, run by Monash University and the Australian Sleep Health Foundation. The Symposium will take place on Tuesday the 23 rd of April 2024 at Monash University and streamed live via Eventbrite. World-leading experts will discuss sleep health in a national and global context, within key focus areas of insomnia, mental health and the clinical unmet need. This symposium will provide a forum to explore new treatment approaches for insomnia, including medicines targeting novel pharmacological mechanisms and psychological therapies. Key speakers include Professor Ruth Benca MD PhD, Chair, Department of Psychiatry and Behavioral Health at Wake Forest School of Medicine; and Professor Robert Adams MBBS MD FRACP FRCP FAASM, a respiratory and sleep physician based at Flinders Medical Centre and Medical Director of Adelaide Institute for Sleep Health (“AISH”). A report by Deloitte Access Economics1, commissioned by the Sleep Health Foundation, cites that almost 1,000 Australian deaths were attributed to sleep disorders in 2019-20, due to increased risk of cardiovascular and metabolic conditions, mental health conditions and reduced mental health. While current medical guidelines recommend cognitive behavioural therapy (“CBTi”) as the first line treatment for insomnia, a shortage of trained clinicians reveals a need for safe, alternative treatment approaches to support better sleep health in adults. Professor Shantha Rajaratnam, Chair of the Sleep Health Foundation and Professor of Sleep and Circadian Medicine at Monash University, said: “Insomnia is the most common sleep disorder and has a significant impact on peoples’ lives. People with insomnia find it hard to fall asleep or stay asleep, or wake up too early. The resulting fatigue from insomnia can drain a person’s energy level and vastly affect their mood, general health, work performance and quality of life. It is vitally important that we are uniting the most skilled professionals in this space to pioneer new treatments. We are delighted to be working in 1 Deloitte Access Economics 2021. Rise and try to shine: The social and economic cost of sleep disorders in Australia. Blacktown: Sleep Health Foundation Avecho Biotechnology Limited | ASX: AVE | ACN: 056 482 403 | ABN: 32 056 482 403 Unit 8A, 2A Westall Road, Hallmarc Business Park, Clayton VIC Australia 3168 avecho.com.au partnership with Avecho to host this industry event with esteemed colleagues from around the world – particularly as the Company is on the cusp of a major regulatory milestone for its CBD-based treatment for insomnia.” Avecho CEO, Dr Paul Gavin, said: “Avecho is excited to be collaborating with Monash, the Sleep Health Foundation and global pioneers in sleep health to support an open and constructive conversation about the progress of treatments for insomnia. We are focused on bringing a CBD-based treatment to market for patients seeking a better night’s sleep – and this discussion will help to examine the role of this new treatment, and alignment with other established therapies. This is an exciting time for our Company.” Avecho is now recruiting 519 patients for the largest sleep study of its kind, globally. Across treatment sites in Melbourne, Sydney, Central Coast, Brisbane and Perth, participants will compare nightly CBD doses of 75 and 150mg CBD with placebo over a 16-week dosing period. Avecho is focused on testing the efficacy of its enhanced CBD formulation to become the first Australian company to sell a CBD treatment for insomnia as an over the counter (“OTC”) medicine. Those who wish to join the event virtually can register by clicking here. People interested in participating in the Avecho Phase III Clinical Trial are invited to visit the clinical trial recruitment portal at cbdinsomniastudy.com. - ENDS This announcement is authorised for release by the Board of Directors of Avecho Biotechnology Limited. Questions related to the announcement are welcome via our InvestorHub platform. Investor + General Enquiries Dr Paul Gavin Chief Executive Officer Avecho Biotechnology Limited +61 3 9002 5000 About Avecho Avecho Biotechnology Limited develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called Tocopheryl Phosphate Mixture (TPM®). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients. Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market and is also developing TPM® to enhance the feed efficiency and health of livestock. Forward-Looking Statements Certain statements in this announcement are forward looking statements. Forward-looking statements can generally be identified by the use of words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, “may”, “assume” and words of similar import. These forward-looking statements speak only as at the date of this announcement. These statements are based on current expectations and beliefs and, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by such forward looking statements. 2 No representation, warranty or assurance (express or implied) is given or made by Avecho that the forwardlooking statements contained in this announcement are accurate, complete, reliable or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, Avecho and its respective officers, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this announcement or any error or omission therefrom. Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, Avecho disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of Avecho since the date of the announcement. Avecho’s major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock. See more here - avecho.com.au 3